CN102793715A - Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury - Google Patents
Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury Download PDFInfo
- Publication number
- CN102793715A CN102793715A CN2012102891707A CN201210289170A CN102793715A CN 102793715 A CN102793715 A CN 102793715A CN 2012102891707 A CN2012102891707 A CN 2012102891707A CN 201210289170 A CN201210289170 A CN 201210289170A CN 102793715 A CN102793715 A CN 102793715A
- Authority
- CN
- China
- Prior art keywords
- sargassan
- kidney injury
- application
- kidney
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of Sargassum polysaccharide in medicine preparation used for treating kidney injury, the Sargassum polysaccharide is an active extract total polysaccharide in Sargassum graminifolium, the invention specifically relates to an application of Sargassum polysaccharide in kidney protection, and an application of Sargassum polysaccharide which can be mixed or individually used as antidotes in the pharmacy fields. The results show that the Sargassum graminifolium polysaccharide has certain protection effect on rat kidney, and can resist the kidney injury caused by medicines and chemicals such as gentamycin, cisplatin and high oxalic acid and the like.
Description
[technical field]
The present invention relates to the kidney injury technical field of pharmaceuticals, specifically, is a kind of sargassan and the application in preparation kidney injury medicine thereof.
[background technology]
In recent years, along with the extensive use of number of chemical material and medicine, also bring negative effect thereupon; Have influence on people health, for example use and bring out renal calculus, cause injury of kidney by the milk powder that contains tripolycyanamide; Cause pathological changes such as kidney inflammatory reaction and proliferation of fibrous tissue; Further cause the renal metabolism dysfunction, blood urea nitrogen, creatinine equal size are increased, finally renal failure can take place.And medicine gentamycin, cisplatin all can cause acute injury of kidney, rise to characteristics rapidly with creatinine in the blood (SCr) and blood urea nitrogen (BUN).Many researchs show that the cisplatin induced nephrotoxicity is the process of a complicacy, and active oxygen is the main cause of cisplatin induced acute injury of kidney.Acute injury of kidney (acute kidney injury; AKI) be one group of clinical common former or Secondary cases impaired renal function; Be to acute renal insufficiency (acute renal insufficiency; ARI or acute kidney dysfunction, AKD) or acute renal failure (acute renal failure, substituting and expansion ARF).At present, many scholars are devoted to alleviate institutes such as gentamycin, cisplatin and ethylene glycol and lead to the research of nephrotoxicity, but applicable clinically medicine is very few.
Polysaccharide has physiological action widely, can remove the activity of free radical, raising activities of antioxidant enzymes and inhibition lipid peroxidation.In recent years; The exploitation of Sargassum and Related product thereof has become research focus; This seminar discovers that a kind of sargassan (SGP) has good effect in aspect such as antioxidation, treatment calcium oxalate stone in vivo and in vitro; Based on this, carried out related experiment to the injury of kidney that ethylene glycol, gentamycin, cisplatin cause.The result shows that sargassan SGP has the effect of the impaired rat kidney of protection aspect.
[summary of the invention]
The objective of the invention is to overcome the deficiency of prior art, a kind of sargassan and the application in preparation kidney injury medicine thereof are provided.
The objective of the invention is to realize through following technical scheme:
The application of a kind of sargassan in preparation kidney injury medicine.
Medicine is made up of blade of grass sargassan and pharmaceutically acceptable carrier.
Described kidney protection medicine is tablet or oral liquid, injection or injectable powder.
The application of a kind of sargassan in preparation kidney injury health product.
Health product are made up of blade of grass sargassan and field of health care products acceptable carrier.
Described kidney protection health product are tablet or oral liquid or capsule preparations.
The injury of kidney that sargassan antagonism is caused by medicine such as gentamycin, cisplatin, high oxalic acid and chemical substance.
Described sargassan is the activity extract in the blade of grass Alga Sgrgassi Enerves, is raw material with the blade of grass Alga Sgrgassi Enerves, utilizes the hot water extraction from the blade of grass Alga Sgrgassi Enerves, to extract polysaccharide and removes albumen and hydrogen peroxide depigmentation after drying obtains sargassan with trichloroacetic acid.Concrete preparation process: get 100 gram blade of grass Alga Sgrgassi Enerves powder, add water 4500ml, after extracting temperature and be 60 ℃, ultrasonic time and being 45min, filter; Filtrating is concentrated into 500ml, and adding volume fraction is 95% ethanol, makes alcoholic acid total concentration reach 80%, leaves standstill 24 hours; The centrifugal 10min of 8000r/min is dissolved to 100ml with resulting deposition water, and the trichloroacetic acid that adds 1 times again removes albumen, removes 2 hours albumen time; Centrifugal then 15min, centrifugal rotational speed is 8000r/min, removes post precipitation and collects supernatant; Behind the adjust pH 4～5, adding mass fraction is that 6～7% hydrogenperoxide steam generators decolour, bleaching time 5～6h; 45 ℃ of bleaching temperatures, the decolouring after drying obtains sargassan.
It is light brown Powdered that the blade of grass sargassan is, and has a little Sargassum fishy smell, water-soluble, is soluble in hot water, is insoluble in high concentration ethanol, ether, the acetone and other organic solvent.Polysaccharide produces the purple ring in the Molish reaction, ninhydrin reaction is negative, and IKI reacts be negative (brown is that color does not change).In thin layer chromatography detection blade of grass sargassan, contain monosaccharide such as galactose, glucose and fucose.Warp is measured the molecular weight of blade of grass sargassan between 5000～20000, and the mass fraction of its sulfate group is 10～15%, and the mass fraction of alduronic acid is 5～15%.
Compared with prior art, good effect of the present invention is:
The existing nephrotoxicity problem that medicine or chemicals are caused is not also fully solved, and is especially seeking aspect the natural active matter efficient, that side effect is light.There is the research report LBP can alleviate the injury of kidney (" Food Science " due to the cisplatin; 2012; 5,268-271), Chinese patent relate to 200810115432.1 have a kidney protective effect ferulic acid and astragaloside combination; Chinese patent relates to 200880113724.X as protectant medium chain length fatty acid of kidney and glyceride, but does not appear in the newspapers about the kidney protective effect of sargassan.Activity extract total polysaccharides in the blade of grass Alga Sgrgassi Enerves of the present invention is external to have remarkable antioxidant activity; It all has the good curing effect to the injury of kidney that ethylene glycol, gentamycin, cisplatin cause the zoopery proof, and this provides new medicine source and selection for the control of clinical injury of kidney.
Activity extract total polysaccharides in the blade of grass Alga Sgrgassi Enerves of the present invention is specifically related to its application aspect the kidney protection, mixes or independent the application as the application of antidote in pharmaceutical field.The result shows that the blade of grass sargassan has the certain protection effect for the kidney of rat, can resist the injury of kidney that is caused by medicines such as gentamycin, cisplatin, high oxalic acid and chemical substance.
[specific embodiment]
The specific embodiment of a kind of sargassan of the present invention and the application in preparation kidney injury medicine thereof below is provided.
Embodiment 1
The application of a kind of sargassan in preparation kidney injury medicine.
Medicine is made up of blade of grass sargassan and pharmaceutically acceptable carrier.
Described kidney protection medicine is tablet or oral liquid, injection or injectable powder.
The application of a kind of sargassan in preparation kidney injury health product.
Health product are made up of blade of grass sargassan and field of health care products acceptable carrier.
Described kidney protection health product are tablet or oral liquid or capsule preparations.
The injury of kidney that sargassan antagonism is caused by medicine such as gentamycin, cisplatin, high oxalic acid and chemical substance.
Described sargassan is the activity extract in the blade of grass Alga Sgrgassi Enerves.
Animal divides into groups and dosage
36 of SD male and healthy (180～220g), be divided into high, medium and low 3 dose groups of matched group, model group, positive drug shenyankangfu tablet group and potassium citrate group and SGP at random, sargassan is respectively 400mg/kg, 100mg/kg, 25mg/kg dosage.Potassium citrate dosage is 50mg/kg, and the nephritis tablet amounts is 600mg/kg.
Modelling and dosage regimen
Ethylene glycol is led to the kidney of rats damage model:
36 of SD rats are divided into 6 groups at random, and 6 every group, handle by following method then: lure stone group (model group) merely: with 1% ethylene glycol+1% ammonium chloride is unique drinking water source, simultaneously every day lumbar injection 1% ethylene glycol+1% ammonium chloride 1ml, lure 2 weeks of stone; Lure stone+sargassan intervention group: with 1% ethylene glycol+1% ammonium chloride is unique drinking water source; Simultaneously every day lumbar injection 1% ethylene glycol+1% ammonium chloride 1ml; Lure stone after 2 weeks; Irritate stomach 10% sargassan high dose 400mg/kg, middle dosage 100mg/kg, low dosage 25mg/kg respectively, irritate 2 weeks of stomach; Blank group: drink deionized water; Positive drug potassium citrate group is unique drinking water source with 1% ethylene glycol+1% ammonium chloride, simultaneously every day lumbar injection 1% ethylene glycol+1% ammonium chloride 1ml, lure stone after 2 weeks, irritate the potassium citrate of stomach 50mg/kg, the administration volume is 10mL/kg.Each is organized rat and all gives identical standard particle feedstuff, ad lib, and (25 ℃ of air-conditioning constant temperature, 12h circulates daytime) raise under identical environmental condition.
Gentamycin causes the kidney of rats damage model:
36 of SD rats are divided into 6 groups at random, 6 every group.Except that matched group, all the other respectively organize 10:00 lumbar injection gentamycin 100mg/kg every day,, the administration volume is 10mL/kg, the matched group lumbar injection gives the normal saline of equal volume.Administration group 14:00 every afternoon administration, the general activity situation of observing rat in the 2h after administration every day is weighed continuous 9 days.Positive drug is the shenyankangfu tablet group.
Cisplatin causes the kidney of rats damage model:
36 of SD rats are divided into 6 groups at random, 6 every group.Blank group and cisplatin model group are irritated stomach distilled water 1mL every day; The basic, normal, high dose groups of SGP; Irritate the SGP solution of stomach corresponding dosage every day; Continuous 15d, cisplatin model group and SGP group disposable celiac injection cisplatin 7.0mg/kg (with weighing machine) causes nephrotoxicity in the time of the 10th day, sets up the injury of kidney animal model.The normal saline of blank group injection equivalent.Observe the general activity situation of rat in the 2h after administration every day, weigh.Positive drug is a shenyankangfu tablet.
Detect index
4h abdominal aortic blood after time administration of above-mentioned three groups of renal injury model rat arts, anticoagulant heparin, centrifuging and taking serum is measured blood parameters: BUN and SCr.
Testing result is following:
1.SGP ethylene glycol is led to the protective effect of kidney of rats damage:
Table 1 SGP leads to the influence of kidney of rats damage to ethylene glycol
Compare with model group: * P＜0.05 * * P＜0.01
Can know by table 1, compare, model group rat blood serum BUN and Scr content significantly raise (P＜0.05) with the blank group.Each dose groups of SGP is compared with model group; The serum BUN of high dose group and Scr content extremely significantly reduce (P＜0.01); The serum Scr content of middle dose groups extremely significantly reduces (P＜0.01); The serum BUN content of dose groups significantly reduces (P＜0.05), and low dose group serum BUN content and model group difference do not have significance, but low dose group serum Scr content and model group difference have significance (P＜0.05).
2.SGP gentamycin is caused the protective effect of kidney of rats damage:
Table 2 SGP causes the influence of kidney of rats damage to gentamycin
Compare with model group: * P＜0.05 * * P＜0.01
Can know by table 2, compare, model group rat blood serum BUN and Scr content significantly raise (P＜0.01) with the blank group.Each dose groups of SGP is compared with model group, and the serum BUN of high dose group and Scr content extremely significantly reduce (P＜0.01), and the serum Scr content of middle dose groups significantly reduces (P＜0.05), and low dose group serum BUN, Scr content and model group difference do not have significance.
3.SGP cisplatin is caused the protective effect of kidney of rats damage:
Table 3 SGP causes the influence of kidney of rats damage to cisplatin
Compare with model group: * P＜0.05 * * P＜0.01
Conclusion: can know by table 3, compare, model group rat blood serum BUN and Scr content significantly raise (P＜0.01) with the blank group.Each dose groups of SGP is compared with model group, and the serum BUN of high dose group and Scr content extremely significantly reduce (P＜0.01), and the serum Scr content of middle dose groups significantly reduces (P＜0.05), and low dose group serum BUN, Scr content and model group difference do not have significance.
Embodiment 2
Kidney protection medicine and health product that the blade of grass sargassan is processed
1, tablet
(1) preparation prescription is following:
(2) preparation technology is:
1. extraction separation: by aforesaid method for distilling from
The blade of grass Alga Sgrgassi EnervesMiddle extraction separation polysaccharide, subsequent use;
2. refining: above-mentioned blade of grass sargassan is through being concentrated into certain density thick paste
3. granulate: get above-mentioned thick paste shape blade of grass sargassan 10g, add ethanol, starch and the dextrin system soft material of an amount of debita spissitudo, cross a sieve (12-14 order) and process granule;
4. dry: that the above-mentioned wet granular that makes is placed on rapid drying in the drying baker, dry 24h under 60 ℃;
5. tabletting: add Pulvis Talci, magnesium stearate, mixing is pressed into 1000, with sucrose sugar coating or film-coat, promptly gets;
6. packing: select the packing of composite aluminium plastic pocket for use, it is wet, ventilative that this composite aluminium plastic pocket be difficult for to pass through, and can not occur the moisture absorption, phenomenon such as softening in storage period.
2, oral solutions
(1) preparation prescription is following:
| The blade of grass sargassan | 10g |
| Sucrose | 70g |
| Citric acid | 2g |
| Sodium benzoate | 1.5g |
| Distilled water | Add to total amount 1000ml |
(2) method for preparing:
1. add a small amount of distilled water at the blade of grass sargassan, heat constantly stirs and makes it dissolving a little;
2. citric acid and sodium benzoate are dissolved in a small amount of distilled water;
3. merge two kinds of liquid, stirring and evenly mixing;
4. add sucrose, adding distil water stirs and makes it to be dissolved into clear solution to 1000ml;
5. liquid filtering is removed insoluble impurities, obtain the liquid preparation of transparent homogeneous;
6. under aseptic condition, be sub-packed in sealing preservation in the sterile ampere bottle.
The present invention considers that the blade of grass sargassan that extracts itself has more special taste; May influence its received degree; Therefore in oral liquid formulations, added a certain amount of correctives to improve its taste; And oral liquid formulations of the present invention done the mouthfeel debugging, and consider economic factor simultaneously, finally selected sucrose and citric acid are as correctives.In addition, because the water-soluble liquid preparation goes mouldy easily, so must add antiseptic, the present invention has selected for use sodium benzoate as antiseptic.
Oral solutions has advantage: dispersion is big, absorbs soon, can promptly bring into play drug effect; Be easy to divided dose, taking convenience is specially adapted to the gerontal patient and swallows inconvenient people; Mouthfeel is good, is easy to accepted etc. by the audient.
3 injection
(1) preparation prescription is following:
| Refining blade of grass sargassan | 100g |
| Sodium chloride | ?5g |
| Sodium benzoate | ?1.5g |
| Water for injection | Add to total amount 10L |
(2) method for preparing:
According to above-mentioned prescription, the well refining blade of grass sargassan of weighing, sodium chloride, sodium benzoate, be mixed with sterile solution after, fill becomes the fractional pack of one bottle of every 10mL, totally 1000 bottles, sterilization back injection.
4 injectable powder
(1) preparation prescription is following:
| Refining blade of grass sargassan | 85-100g |
| Glycine | 0-15g |
| Mannitol | 0-15g |
| Polyethylene Glycol | 0-15g |
| Lactose | 0-15g |
| The PH regulator | 0-5g |
(2) method for preparing:
According to above-mentioned prescription, the well refining blade of grass sargassan of weighing is chosen one or more of glycine, mannitol, Polyethylene Glycol, lactose; Regulating PH is 7; After being mixed with sterile solution, after aseptic and heat source check were qualified, fill became the fractional pack of one bottle of every 10mL; Carry out lyophilization, injection after the lyophilizing.
5 capsules
(1) preparation prescription is following:
(2) method for preparing:
According to above-mentioned prescription, the good blade of grass sargassan of weighing is granulated with starch slurry, and dry back granulate is filled with the hard capsule filling machine then, seals again, promptly gets.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the present invention's design; Can also make some improvement and retouching, these improvement and retouching also should be regarded as in protection scope of the present invention.
Claims (8)
1. the application of sargassan in preparation kidney injury medicine.
2. the application of a kind of sargassan as claimed in claim 1 in preparation kidney injury medicine is characterized in that described kidney injury is the injury of kidney that gentamycin, cisplatin, high oxalic acid medicine and chemical substance cause.
3. the application of a kind of sargassan as claimed in claim 1 in preparation kidney injury medicine; It is characterized in that; The molecular weight of described sargassan is between 5000～20000, and the mass fraction of its sulfate group is 10～15%, and the mass fraction of alduronic acid is 5～15%.
4. the application of sargassan in preparation kidney injury health product.
5. the application of a kind of sargassan as claimed in claim 4 in preparation kidney injury health product is characterized in that described kidney injury is the kidney injury that gentamycin, cisplatin, high oxalic acid medicine and chemical substance cause.
6. the application of a kind of sargassan as claimed in claim 4 in preparation kidney injury health product; It is characterized in that; The molecular weight of described sargassan is between 5000～20000, and the mass fraction of its sulfate group is 10～15%, and the mass fraction of alduronic acid is 5～15%.
7. the method for distilling of a sargassan; It is characterized in that its concrete steps are: with the blade of grass Alga Sgrgassi Enerves is raw material, utilizes the hot water extraction from the blade of grass Alga Sgrgassi Enerves, to extract polysaccharide; And after removing albumen and hydrogen peroxide depigmentation with trichloroacetic acid, drying obtains sargassan.
8. the method for distilling of a kind of sargassan as claimed in claim 7 is characterized in that, gets 100 gram blade of grass Alga Sgrgassi Enerves powder, adds water 4500ml; After extracting temperature and be 60 ℃, ultrasonic time and being 45min, filter, filtrating is concentrated into 500ml, adding volume fraction is 95% ethanol; Make alcoholic acid quality total concentration reach 80%, left standstill 24 hours, the centrifugal 10min of 8000r/min; Resulting deposition water is dissolved to 100ml, and the trichloroacetic acid that adds 1 times again removes albumen, removes 2 hours albumen time; Centrifugal then 15min, centrifugal rotational speed is 8000r/min, removes post precipitation and collects supernatant; Behind the adjust pH 4～5, adding mass fraction is that 6～7% hydrogenperoxide steam generators decolour, bleaching time 5～6h; 45 ℃ of bleaching temperatures, the decolouring after drying obtains sargassan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102891707A CN102793715A (en) | 2012-08-14 | 2012-08-14 | Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102891707A CN102793715A (en) | 2012-08-14 | 2012-08-14 | Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102793715A true CN102793715A (en) | 2012-11-28 |
Family
ID=47193184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102891707A Pending CN102793715A (en) | 2012-08-14 | 2012-08-14 | Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102793715A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104829740A (en) * | 2015-05-12 | 2015-08-12 | 上海海洋大学 | Method for synchronously extracting sargassum graminifolium polysaccharide and sargassum graminifolium polyphenol from sargassum graminifolium |
| CN104829738A (en) * | 2015-05-12 | 2015-08-12 | 上海海洋大学 | Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes |
| CN106420879A (en) * | 2016-10-27 | 2017-02-22 | 福建农林大学 | Nanoparticles capable of assisting in lowering blood sugar and preparation method thereof |
| CN107573544A (en) * | 2017-07-31 | 2018-01-12 | 浦江县昂宝生物技术有限公司 | The preparation method of edible packing membrane based on sargassan |
| CN108420834A (en) * | 2018-06-07 | 2018-08-21 | 艾苛密（上海）健康科技股份有限公司 | Repair of cartilage marine algae extract and preparation method thereof |
| CN109321467A (en) * | 2018-11-06 | 2019-02-12 | 杭州园泰生物科技有限公司 | The pilot scale culture of Wa Shi sargassum and the technique for extracting polysaccharide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371852A (en) * | 2008-09-26 | 2009-02-25 | 广西壮族自治区兽医研究所 | Method for preventing and treating leukoderma of prawn |
| CN102488700A (en) * | 2011-12-23 | 2012-06-13 | 上海海洋大学 | Application of sargassan to preparation of medicament for preventing and treating urinary calculus |
-
2012
- 2012-08-14 CN CN2012102891707A patent/CN102793715A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371852A (en) * | 2008-09-26 | 2009-02-25 | 广西壮族自治区兽医研究所 | Method for preventing and treating leukoderma of prawn |
| CN102488700A (en) * | 2011-12-23 | 2012-06-13 | 上海海洋大学 | Application of sargassan to preparation of medicament for preventing and treating urinary calculus |
Non-Patent Citations (3)
| Title |
|---|
| 周峰等: "虫草多糖对庆大霉素诱发的急性肾衰的预防作用", 《药学与临床研究》 * |
| 张朝燕等: "草叶马尾藻多糖对高草酸诱致大鼠肾损伤的保护作用研究", 《第十一届全国青年药学工作者最新科研成果交流会论文集》 * |
| 王黎等: "灵芝多糖对顺铂致大鼠肾损伤保护作用的实验研究", 《中成药》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104829740A (en) * | 2015-05-12 | 2015-08-12 | 上海海洋大学 | Method for synchronously extracting sargassum graminifolium polysaccharide and sargassum graminifolium polyphenol from sargassum graminifolium |
| CN104829738A (en) * | 2015-05-12 | 2015-08-12 | 上海海洋大学 | Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes |
| CN106420879A (en) * | 2016-10-27 | 2017-02-22 | 福建农林大学 | Nanoparticles capable of assisting in lowering blood sugar and preparation method thereof |
| CN107573544A (en) * | 2017-07-31 | 2018-01-12 | 浦江县昂宝生物技术有限公司 | The preparation method of edible packing membrane based on sargassan |
| CN108420834A (en) * | 2018-06-07 | 2018-08-21 | 艾苛密（上海）健康科技股份有限公司 | Repair of cartilage marine algae extract and preparation method thereof |
| CN108420834B (en) * | 2018-06-07 | 2021-04-23 | 艾苛密（上海）健康科技股份有限公司 | Seaweed extract for cartilage repair and preparation method thereof |
| CN109321467A (en) * | 2018-11-06 | 2019-02-12 | 杭州园泰生物科技有限公司 | The pilot scale culture of Wa Shi sargassum and the technique for extracting polysaccharide |
| CN109321467B (en) * | 2018-11-06 | 2021-03-26 | 杭州园泰生物科技有限公司 | Large-scale culture of Sargassum vachellii and process for extracting polysaccharide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101889027B (en) | Alginic acid with low molecular weight, its salts, uses, preparative methods, pharmaceutical compositions and foods | |
| CN102793715A (en) | Sargassum polysaccharide and application of Sargassum polysaccharide in medicine preparation used for treating kidney injury | |
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| CN102302091B (en) | Chinese herb medicine feed additive used for treating low sexual function of male breeding poultry and preparation method thereof | |
| CN102228151A (en) | Traditional Chinese medicine feed additive for treating hypogonadism of male breeding stock and preparation method thereof | |
| CN103283886A (en) | Active ginseng tea | |
| CN101926834B (en) | Morchella conica granules and preparation method and application thereof | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN108014150A (en) | Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared | |
| CN102068494A (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| KR20190124197A (en) | Chinese herbal composition for the treatment of tumor and its manufacturing method and application | |
| CN110664883B (en) | A pharmaceutical composition with vital essence generation effect | |
| CN111494564B (en) | Preparation method of compound liver-protecting and alcohol-dispelling tablet | |
| CN105168336A (en) | Natural medicine composition for adjusting diabetes immune and metabolism functions and preparation method of natural medicine composition | |
| CN103566282B (en) | A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN115444922B (en) | Anti-fatigue medicinal and edible composition and application thereof | |
| CN103830280B (en) | Preparation method of spirulina extract | |
| KR20130015341A (en) | Transparent soap composition for washing skin contaminated by radioactivity skin and manufacturing of the same | |
| CN109602759A (en) | The purposes of kusamaki broad-leaved podocarpus seed and receptacle polysaccharide | |
| CN1401365A (en) | Chinese health medicine | |
| CN102726724A (en) | Food liver nourishing tea granules used for preventing fatty liver | |
| CN102727867B (en) | Antineoplastic pharmaceutical composition and application thereof, kit and package | |
| CN107510813A (en) | Pharmaceutical composition for reducing side effects of cancer treatment drugs, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121128 |